Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J Biol Chem. 2023 Sep;299(9):105176. doi: 10.1016/j.jbc.2023.105176. Epub 2023 Aug 18.
Substance abuse is on the rise, and while many people may use illicit drugs mainly due to their rewarding effects, their societal impact can range from severe, as is the case for opioids, to promising, as is the case for psychedelics. Common with all these drugs' mechanisms of action are G protein-coupled receptors (GPCRs), which lie at the center of how these drugs mediate inebriation, lethality, and therapeutic effects. Opioids like fentanyl, cannabinoids like tetrahydrocannabinol, and psychedelics like lysergic acid diethylamide all directly bind to GPCRs to initiate signaling which elicits their physiological actions. We herein review recent structural studies and provide insights into the molecular mechanisms of opioids, cannabinoids, and psychedelics at their respective GPCR subtypes. We further discuss how such mechanistic insights facilitate drug discovery, either toward the development of novel therapies to combat drug abuse or toward harnessing therapeutic potential.
物质滥用呈上升趋势,尽管许多人可能主要由于其奖赏效应而使用非法药物,但它们对社会的影响范围从严重(如阿片类药物)到有希望(如迷幻剂)不等。所有这些药物的作用机制都与 G 蛋白偶联受体(GPCR)有关,这些受体是这些药物介导醉酒、致命性和治疗效果的核心。芬太尼等阿片类药物、四氢大麻酚等大麻素类药物和麦角酸二乙基酰胺等迷幻剂都直接与 GPCR 结合,启动信号转导,从而引发它们的生理作用。本文综述了最近的结构研究,并提供了在各自 GPCR 亚型中阿片类药物、大麻素类药物和迷幻剂的分子机制的见解。我们还进一步讨论了这些机制上的见解如何促进药物发现,无论是开发新的疗法来对抗药物滥用,还是利用治疗潜力。